Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protein phosphatase 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    271 result(s) found for: Protein phosphatase 2. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-004737-85 Sponsor Protocol Number: 1.3 Start Date*: 2018-12-11
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Alkaline Phosphatase to prevent ischemia reperfusion injury in living kidney transplantation
    Medical condition: Ischemia reperfusion injury in living donor kidney transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007406-11 Sponsor Protocol Number: ENB-002-08 Start Date*: 2009-02-25
    Sponsor Name:Enobia Canada Limited Partnership
    Full Title: A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of ENB-0040 (Enobia’s human recombinant tissue non-specific alkaline phosphatase fusion protein) in up to 6 Severely Aff...
    Medical condition: Infantile Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003153-42 Sponsor Protocol Number: ENB-008-10 Start Date*: 2017-08-03
    Sponsor Name:Alexion Pharma GmbH
    Full Title: Extension Study of Protocol ENB-006-09 Evaluating the Long-Term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Children with Hyp...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001128-52 Sponsor Protocol Number: ENB-006-09 Start Date*: 2015-05-28
    Sponsor Name:Alexion Pharma International Sàrl
    Full Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue-No...
    Medical condition: Hypophosphatasia (HPP)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019850-42 Sponsor Protocol Number: ENB-010-10 Start Date*: 2011-03-04
    Sponsor Name:Alexion Pharma GmbH
    Full Title: An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants a...
    Medical condition: Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme. With deficiency of Tissue-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-002241-39 Sponsor Protocol Number: BO 18192 Start Date*: 2005-11-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented a...
    Medical condition: Advanced (stage IIIB or IV) NSCLC previously treated with 4 cycles of a platinum-based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SI (Completed) GB (Completed) AT (Completed) LT (Completed) SK (Completed) PT (Prematurely Ended) DE (Completed) DK (Completed) CZ (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001831-38 Sponsor Protocol Number: ENB-009-10 Start Date*: 2017-05-09
    Sponsor Name:Alexion Pharma GmbH
    Full Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-009369-32 Sponsor Protocol Number: ENB-003-08 Start Date*: 2009-03-30
    Sponsor Name:Alexion Pharma GmbH
    Full Title: Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children with Hypophosphatasia (HPP)
    Medical condition: Infantile hypoposphatasia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002648-10 Sponsor Protocol Number: ADDI-D Start Date*: 2014-03-04
    Sponsor Name:Bruno Farmaceutici S.p.a.
    Full Title: THE EFFECT OF A DAILY AND WEEKLY ADMINISTRATION OF DIFFERENT DOSES OF CALCIDIOL ON 25(OH)D3 SERUM LEVELS AND ON MINERAL AND BONE METABOLIC MARKERS IN POSTMENOPAUSAL FEMALE SUBJECTS OVER 55 YEARS OF...
    Medical condition: Postmenopausal female subjects with inadequate levels or deficit of 25(OH)D3
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000809-39 Sponsor Protocol Number: AA-HPP-405 Start Date*: 2016-02-04
    Sponsor Name:Alexion Pharma International Sàrl
    Full Title: An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nonspecific alkaline phosphatase fusion protein) Treatment for Patients with Infantile- or Juvenile-o...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005182-35 Sponsor Protocol Number: BO20906 Start Date*: 2008-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem...
    Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003220-19 Sponsor Protocol Number: BO18602 Start Date*: 2005-12-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, a...
    Medical condition: Advanced (stage IIIB or IV) non-small cell lung cancer (NSCLC) previously treated with a platinum-based chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SI (Completed) GB (Completed) BE (Completed) LT (Completed) SK (Completed) HU (Completed) AT (Prematurely Ended) DK (Completed) PT (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005683-21 Sponsor Protocol Number: ENM-EA-030 Start Date*: 2012-10-09
    Sponsor Name:Medizinische Universität Graz
    Full Title: Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
    Medical condition: Primary hyperparathyroidism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000752-41 Sponsor Protocol Number: E7050-701 Start Date*: 2011-10-31
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003131-35 Sponsor Protocol Number: AA-HPP-208 Start Date*: 2016-04-19
    Sponsor Name:Alexion Pharma GmbH
    Full Title: A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset Hypophosphatasia
    Medical condition: Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme. With deficiency of Tissue-no...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003894-18 Sponsor Protocol Number: M07CCL Start Date*: 2008-01-30
    Sponsor Name:NKI-AVL
    Full Title: Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma
    Medical condition: Non-small cell lung cancer locally advanced
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004943-32 Sponsor Protocol Number: ICORG1124NSABPB47 Start Date*: 2011-12-13
    Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland
    Full Title: ICORG 11-24-NSABP PROTOCOL B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cy...
    Medical condition: Node positive, or high risk node negative invasive breast cancer in patients that are HER 2 low
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021587-15 Sponsor Protocol Number: ICORG10-04NSABP-B46I Start Date*: 2010-09-08
    Sponsor Name:ICORG
    Full Title: A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Medical condition: Adjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003444-30 Sponsor Protocol Number: C0743T12 Start Date*: 2007-05-15
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003245-29 Sponsor Protocol Number: SA652013 Start Date*: 2016-12-19
    Sponsor Name:Amsterdam AMC, locatie AMC
    Full Title: Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after Roux-en-Y gastric bypass and Sleeve Gastrectomy
    Medical condition: Prevention of symptomatic gallstone disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:12:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA